People | November 25, 2024
Surendralal Karsanbhai elected to Merck Board of Directors
With the addition of Karsanbhai, the Merck board will consist of 13 members
With the addition of Karsanbhai, the Merck board will consist of 13 members
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Subscribe To Our Newsletter & Stay Updated
